BB&T Securities’s Charles River Laboratories CRL Stock Holding History

BB&T Securities’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.05M	Buy	7,917 +1,556	+24%	+$209K	0.01%	779
2019 Q2	$902K	Buy	6,361 +315	+5%	+$42.7K	0.01%	858
2019 Q1	$878K	Buy	6,046 +697	+13%	+$91.6K	0.01%	852
2018 Q4	$605K	Sell	5,349 -305	-5%	-$38.2K	0.01%	913
2018 Q3	$760K	Buy	5,654 +2,750	+95%	+$339K	0.01%	912
2018 Q2	$326K	Buy	2,904 +76	+3%	+$8.22K	﹤0.01%	1243
2018 Q1	$301K	Buy	2,828 +256	+10%	+$27.6K	﹤0.01%	1237
2017 Q4	$281K	Sell	2,572 -104	-4%	-$11.3K	﹤0.01%	1211
2017 Q3	$289K	Buy	+2,676	New	+$275K	﹤0.01%	1175

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB&T Securities's CRL Position: Q3 2019 in Review

BB&T Securities increased its Charles River Laboratories (CRL) stake by 24% in Q3 2019, buying an estimated $209K and bringing the position to 7,917 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #779.

BB&T Securities first reported a position in CRL in Q3 2017 and has held it in 9 quarters since. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

BB&T Securities held 7,917 shares of Charles River Laboratories worth $1.05M as of Q3 2019.
BB&T Securities bought 1,556 Charles River Laboratories shares in Q3 2019, an estimated $209K.
Charles River Laboratories made up 0.01% of BB&T Securities's portfolio in Q3 2019, its #779 holding.
BB&T Securities first reported a position in Charles River Laboratories in Q3 2017 and has held it in 9 quarters since.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.